Sunkaru Touray1, Rahul N Sood2, Daniel Lindstrom3, Jonathan Holdorf3, Sumera Ahmad4, Daniel B Knox3, Andres F Sosa5. 1. Division of Pulmonary, Allergy & Critical Care, Department of Pulmonary Allergy & Critical Care Medicine, UMass Memorial Medical Centre, University of Massachusetts Medical School, Worcester, MA, 01605, USA. Sunkaru.Touray@umassmemorial.org. 2. Lahey Hospital & Medical Center, Burlington, MA, USA. 3. Division of Pulmonary, Allergy & Critical Care, Department of Pulmonary Allergy & Critical Care Medicine, UMass Memorial Medical Centre, University of Massachusetts Medical School, Worcester, MA, 01605, USA. 4. Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, USA. 5. Baptist Hospital of Miami, Miami, FL, USA.
Abstract
PURPOSE: Complicated parapneumonic effusions and empyema are a leading cause of morbidity in the United States with over 1 million admissions annually and a mortality rate that remains high in spite of recent advances in diagnosis and treatment. The identification of high risk patients is crucial for improved management and the provision of cost-effective care. The RAPID score is a scoring system comprised of the following variables: renal function, age, purulence, infection source, and dietary factors and has been shown to predict outcomes in patients with pleural space infections. METHODS: In a single center retrospective study, we evaluated 98 patients with complicated parapneumonic effusions and empyema who had tube thoracostomy (with or without Intrapleural fibrinolytic therapy) and assessed treatment success rates, mortality, length of hospital stay, and direct hospitalization costs stratified by three RAPID score categories: low-risk (0-2), medium risk (3-4), and high-risk (5-7) groups. RESULTS: Treatment success rate was 71%, and the 90 day mortality rate was 12%. There was a positive-graded association between the low, medium and high RAPID score categories and mortality, (5.3%, 8.3% and 22.6%, respectively), length of hospital stay (10, 21, 19 days, respectively), and direct hospitalization costs ($19,909, $36,317 and $43,384, respectively). CONCLUSION: Our findings suggest that the RAPID score is a robust tool which could be used to identify patients with complicated parapneumonic effusions and empyema who may be at an increased risk of mortality, prolonged hospitalization, and who may incur a higher cost of treatment. Randomized controlled trials identifying the most effective initial treatment modality for medium- and high-risk patients are needed.
PURPOSE: Complicated parapneumonic effusions and empyema are a leading cause of morbidity in the United States with over 1 million admissions annually and a mortality rate that remains high in spite of recent advances in diagnosis and treatment. The identification of high risk patients is crucial for improved management and the provision of cost-effective care. The RAPID score is a scoring system comprised of the following variables: renal function, age, purulence, infection source, and dietary factors and has been shown to predict outcomes in patients with pleural space infections. METHODS: In a single center retrospective study, we evaluated 98 patients with complicated parapneumonic effusions and empyema who had tube thoracostomy (with or without Intrapleural fibrinolytic therapy) and assessed treatment success rates, mortality, length of hospital stay, and direct hospitalization costs stratified by three RAPID score categories: low-risk (0-2), medium risk (3-4), and high-risk (5-7) groups. RESULTS: Treatment success rate was 71%, and the 90 day mortality rate was 12%. There was a positive-graded association between the low, medium and high RAPID score categories and mortality, (5.3%, 8.3% and 22.6%, respectively), length of hospital stay (10, 21, 19 days, respectively), and direct hospitalization costs ($19,909, $36,317 and $43,384, respectively). CONCLUSION: Our findings suggest that the RAPID score is a robust tool which could be used to identify patients with complicated parapneumonic effusions and empyema who may be at an increased risk of mortality, prolonged hospitalization, and who may incur a higher cost of treatment. Randomized controlled trials identifying the most effective initial treatment modality for medium- and high-risk patients are needed.
Entities:
Keywords:
Complicated parapneumonic effusions; Cost of care; Empyema; Intrapleural fibrinolytic therapy; Mortality; Tube thoracostomy; Video assisted thoracoscopic surgery
Authors: M Falguera; J Carratalà; S Bielsa; C García-Vidal; A Ruiz-González; I Chica; F Gudiol; J M Porcel Journal: Eur Respir J Date: 2011-05-12 Impact factor: 16.671
Authors: Sarah M Menzies; Najib M Rahman; John M Wrightson; Helen E Davies; Robert Shorten; Stephen H Gillespie; Christopher W H Davies; Nick A Maskell; Andrew A Jeffrey; Y C Gary Lee; Robert J O Davies Journal: Thorax Date: 2011-04-01 Impact factor: 9.139
Authors: J Letheulle; M Kerjouan; F Bénézit; B De Latour; P Tattevin; C Piau; H Léna; B Desrues; Y Le Tulzo; S Jouneau Journal: Rev Mal Respir Date: 2015-01-13 Impact factor: 0.622
Authors: Najib M Rahman; Nicholas A Maskell; Alex West; Richard Teoh; Anthony Arnold; Carolyn Mackinlay; Daniel Peckham; Chris W H Davies; Nabeel Ali; William Kinnear; Andrew Bentley; Brennan C Kahan; John M Wrightson; Helen E Davies; Clare E Hooper; Y C Gary Lee; Emma L Hedley; Nicky Crosthwaite; Louise Choo; Emma J Helm; Fergus V Gleeson; Andrew J Nunn; Robert J O Davies Journal: N Engl J Med Date: 2011-08-11 Impact factor: 91.245
Authors: Pedro Rodríguez Suárez; Jorge Freixinet Gilart; José María Hernández Pérez; Mohamed Hussein Serhal; Antonio López Artalejo Journal: Med Sci Monit Date: 2012-07
Authors: Nick A Maskell; Sarah Batt; Emma L Hedley; Christopher W H Davies; Stephen H Gillespie; Robert J O Davies Journal: Am J Respir Crit Care Med Date: 2006-07-13 Impact factor: 21.405